STRATEC SE : High dependency on the final quarter
>Top-line guidance reduction factored in - Stratec expects its consolidated sales on a constant-currency basis to fall slightly short of the previous year’s figure in its adjusted guidance for FY 2023 (previously stable or slight sales growth) at constant currencies. The acquisition of Natech Plastic, completed as of 1 July 2023, is expected to contribute around 3.0 percentage points to sales volumes. We now forecast an organic decline of -6.5% (previously -1.0%) for ...STRATEC Biomedical designs and manufactures automation solutions and technologies for use mainly in in-vitro diagnostics (IVD) and in other regulated markets. IVD refers to those diagnostics activities performed outside the body in a glass or in test receptacles in a laboratory. Co. operates through two segments: Instrumentation and All Other. In the Instrumentation segment, Co. designs and manufactures fully automated analyzer systems for its clinical diagnostics and biotechnology customers. In its all other segment, Co. develops workflow software for networking several analyzer systems and develops and sells scientific materials and technologies such as nucleic acid purification.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.